5,146 Johnson & Johnson $JNJ Shares Sold by Heritage Investors Management Corp

Key Points

• Heritage Investors Management Corp. reduced its Johnson & Johnson stake by 3.2%, selling 5,146 shares and retaining 155,563 shares valued at approximately $41.2 million. Institutional investors collectively own 69.55% of JNJ.
• New clinical data strengthened the outlook for J&J’s Impella heart pumps, with studies showing favorable outcomes in high-risk procedures and a separate trial reporting a 94% success rate. The ongoing PROTECT IV trial could provide further support for the device’s growth potential.
• JNJ reported quarterly adjusted EPS of $2.59, ahead of the $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. The company announced a quarterly dividend of $1.34, equivalent to a 2.0% yield, though analysts noted the stock may be fully valued after its recent gains.

Heritage Investors Management Corp reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,563 shares of the company's stock after selling 5,146 shares during the period. Johnson & Johnson makes up 1.2% of Heritage Investors Management Corp's portfolio, making the stock its 23rd biggest holding. Heritage Investors Management Corp's holdings in Johnson & Johnson were worth $41,184,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in JNJ. Outlook Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter valued at $28,000. Matrix Trust Co increased its stake in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares during the last quarter. Montgomery Financial Services LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $43,000. Hanseatic Management Services Inc. purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $52,000. Finally, Polaris Financial Partners bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $56,000. Institutional investors own 69.55% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
• Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
• Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Analyst Upgrades and Downgrades

Several research analysts have recently commented on JNJ shares. Erste Group Bank lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. Leerink Partners lowered their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 14th. HSBC lifted their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. TD Cowen reissued a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $275.92.

Johnson & Johnson Stock Down 0.9%

Shares of JNJ opened at $270.81 on Tuesday. The firm has a market cap of $651.93 billion, a P/E ratio of 41.03, a P/E/G ratio of 2.68 and a beta of 0.21. The stock has a 50 day simple moving average of $265.74 and a two-hundred day simple moving average of $247.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1 year low of $185.12 and a 1 year high of $282.02.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business's revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is presently 81.21%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 64,515 shares of company stock valued at $17,271,766 over the last three months. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.